Australia markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
48.49-0.32 (-0.66%)
At close: 04:00PM EST
48.92 +0.43 (+0.89%)
Pre-market: 07:00AM EST
Full screen
Trade prices are not sourced from all markets
Previous close48.81
Bid0.00 x 800
Ask0.00 x 800
Day's range48.33 - 48.80
52-week range36.91 - 58.10
Avg. volume2,537,696
Market cap122.893B
Beta (5Y monthly)0.43
PE ratio (TTM)17.44
Earnings dateN/A
Forward dividend & yield1.75 (3.60%)
Ex-dividend date26 May 2022
1y target estN/A
  • Bloomberg

    Deutsche Bank, UBS in Focus as Wall Street Sends Mixed Signals

    (Bloomberg) -- As earnings season gathers pace, a slew of weak results and a hawkish European Central Bank risk spoiling the rally that spurred European equities to their best-ever start to a year. Most Read from BloombergAdani Tries to Calm Investors With 413-Page Hindenburg RebuttalAdani Rout Hits $68 Billion as Fight With Hindenburg IntensifiesRussia Can’t Replace the Energy Market Putin BrokeHistoric Crash for Memory Chips Threatens to Wipe Out EarningsThis week, it’s the turn of banks and p

  • Motley Fool

    Could This Vaccine Become Sanofi's Latest Blockbuster?

    Sanofi (NASDAQ: SNY) and AstraZeneca's (NASDAQ: AZN) application for the respiratory syncytial virus (RSV) vaccine candidate called nirsevimab was recently accepted for review by the U.S. Food and Drug Administration (FDA) as a protective option for all infants. Nirsevimab is known by the trade name Beyfortus in the European Union and the United Kingdom, and the FDA expects to make an approval decision on the RSV vaccine in the third quarter of this year.

  • Zacks

    Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Sanofi (SNY) closed at $48.49, marking a -0.66% move from the previous day.